INBX
NASDAQ · Biotechnology
Inhibrx Biosciences Inc
$60.92
-3.95 (-6.09%)
Open$63.89
Previous Close$64.87
Day High$64.29
Day Low$60.23
52W High$94.57
52W Low$10.81
Volume—
Avg Volume177.7K
Market Cap993.77M
P/E Ratio—
EPS$-7.22
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
-70.2% upside
Current
$60.92
$60.92
Target
$18.13
$18.13
$12.39
$18.13 avg
$27.56
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 171.9K | 568.5K | 384.43M |
| Net Income | 1.46B | 4.33B | -115,444,062 |
| Profit Margin | 843,786.0% | 801,596.7% | -30.0% |
| EBITDA | 1.46B | 4.59B | -155,644,267 |
| Free Cash Flow | — | — | -85,235,104 |
| Rev Growth | -69.8% | -69.8% | -5.8% |
| Debt/Equity | — | — | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |